ストックスクリーナーアプリを入手
0.50
5.26%
0.025
アフターアワーズ：
.47
-0.03
-6.00%
Silexion Therapeutics Corp (SLXN) 最新ニュース
Silexion Therapeutics (SLXN) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Stock ReactionAI Expert Picks - Newser
Silexion Therapeutics (SLXN): Modest Gains as Stock Holds Key Support at $0.46Percent Above MA - Newser
Silexion Therapeutics prices new warrants exercise deal at $0.50 to raise $1M - MSN
Silexion Therapeutics Stock Surges 97% on Phase 2/3 Trial Approval - Meyka
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN - TechStock²
Silexion Therapeutics(SLXN) Stock Options Chain | Quotes & News - Moomoo
Biotech Stock Silexion Therapeutics Corp. (NASDAQ: SLXN) Soars on Update and First Quarter Results - Investorideas.com
Silexion Therapeutics (SLXN) spikes as investors react to mid-May clinical-trial milestones and fresh financing - Quiver Quantitative
Silexion’s Cancer Trial Push Puts Focus on Cash - TechStock²
Silexion Therapeutics Posts Wider Q1 Loss, Advances SIL204 Into Phase 2/3 Trials; Stock Up - RTTNews
Silexion Therapeutics (SLXN) Gained +56.13% — Can It Break $0.44? 2026-05-20Volatility Smile - Newser
Silexion (NASDAQ: SLXN) 10-K amendment corrects internal control date - Stock Titan
Silexion Therapeutics (SLXN) Q1 2026 Earnings Surprise: EPS $-0.85, Up SignificantTrending Community Stocks - Newser
Silexion Therapeutics 1Q Research and Development Approximately $1.4M >SLXN - Moomoo
Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - Sahm
Silexion Therapeutics (SLXN) Declines -5.54% Amid Market Weakness 2026-05-18{涓偂鍓爣棰榼 - Newser
Silexion Therapeutics (SLXN) Stock: Down -5.54%, Support Test at $0.26 2026-05-18{涓偂鍓爣棰榼 - Newser
Silexion Shares Decline After Update on German Regulatory Review - MSN
Silexion reports Q1 results, advances SIL204 clinical path - grafa.com
Silexion Therapeutics Reports Q1 2026 Financial Results and Submits Phase 2/3 Clinical Trial Application for Pancreatic Cancer in Germany - Minichart
Silexion Therapeutics reports Q1 2026 net loss $2.7M, cash $2.4M; SIL204 Phase 2/3 approval - TradingView
Pancreatic cancer RNAi trial moves ahead as Silexion ramps up spending - Stock Titan
Silexion (NASDAQ: SLXN) Q1 loss widens as SIL204 moves into Phase 2/3 - Stock Titan
TradingKey - TradingKey
Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds - Sahm
Silexion (SLXNW) Drops -22.58% — Key Support at $0.01 2026-05-15Earnings Miss Stocks - newser.com
Silexion Therapeutics Announces Warrant Inducement Financing Agreement - TipRanks
Silexion Therapeutics Corp 1Q 2026: Net loss $2.7M, EPS ($0.85) — 10-Q Summary - TradingView
Silexion Therapeutics (NASDAQ: SLXN) posts higher Q1 loss and flags going concern risk - Stock Titan
Silexion Therapeutics Corp Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Warrant deal gives Silexion (NASDAQ: SLXN) $1.0M cash and new overhang - Stock Titan
Lind Global files 13G/A: 212,500 warrants in Silexion (SLXN) - Stock Titan
Silexion raises $1M through warrant exercise at $0.50/share - Investing.com
Cancer biotech Silexion swaps warrant deal for $1M in new funding - Stock Titan
Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer - Sahm
Silexion Announces Positive Preclinical Data for SIL204 Therapy - TipRanks
Silexion reports preclinical data on SIL204 in pancreatic cancer By Investing.com - Investing.com India
Silexion (SLXN) reports immune-related SIL204 signal in KRAS pancreatic cancer - Stock Titan
SLXNSilexion Therapeutics Corp stock news, filings & ratings - Quantisnow
Silexion Therapeutics reports positive preliminary immunotherapy findings for SIL204 in KRAS-driven pancreatic cancer - marketscreener.com
Silexion reports preclinical data on SIL204 in pancreatic cancer - Investing.com
Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings For Sil204 In Kras-Driven Pancreatic Cancer - TradingView
Silexion Therapeutics Reports Positive Preclinical Results for SIL204 in KRAS-Mutated Pancreatic Cancer Study - Quiver Quantitative
Silexion Therapeutics Reports Positive Preliminary - GlobeNewswire
Silexion Therapeutics initiates GMP clinical batch manufacturing of SIL204 - TipRanks
Silexion starts GMP manufacturing of SIL204 and gets Phase 2/3 trial approval for pancreatic cancer. - Pluang
Silexion Therapeutics Announces GMP Clinical Supply Manufacturing Initiation for SIL204 and New Approval – SEC 8-K Filing May 2026 - Minichart
Silexion Advances SIL204 With Manufacturing and Trial Approval - TipRanks
Silexion (NASDAQ: SLXN) advances SIL204 with GMP batches and Phase 2/3 ethics approval - Stock Titan
Silexion begins clinical manufacturing of SIL204 for phase 2/3 trial By Investing.com - Investing.com South Africa
Silexion begins clinical manufacturing of SIL204 for phase 2/3 trial - Investing.com
Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center - The Manila Times
2.98%
1.33%
大文字化:
|
ボリューム (24 時間):